Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Carboplatin, Everolimus, and Prednisone in Treating Patients With Metastatic Prostate Cancer That Progressed After Docetaxel

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01051570
Recruitment Status : Completed
First Posted : January 18, 2010
Results First Posted : August 25, 2014
Last Update Posted : December 1, 2020
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Elisabeth Heath, Barbara Ann Karmanos Cancer Institute

Brief Summary:

RATIONALE: Drugs used in chemotherapy, such as carboplatin and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving carboplatin together with everolimus and prednisone may kill more tumor cells.

PURPOSE: This phase II trial is studying how well giving carboplatin together with everolimus and prednisone works in treating patients with metastatic prostate cancer that progressed after docetaxel.

Condition or disease Intervention/treatment Phase
Prostate Cancer Drug: carboplatin Drug: RAD 001 Drug: prednisone Other: laboratory biomarker analysis Other: pharmacological study Phase 2

Detailed Description:



  • To evaluate the time to progression (TTP) achieved with carboplatin and everolimus in patients with castrate resistant metastatic prostate cancer that progressed after docetaxel-based chemotherapy.


  • To evaluate the safety of this regimen.
  • To assess the PSA response rate in patients treated with this regimen.
  • To evaluate the overall survival (OS) outcome in these patients.
  • To investigate the association of TTP and PSA response rate with correlative markers, such as phospho mTOR, pAKT, and p70S6.
  • To evaluate the pharmacokinetics of this regimen.
  • To explore the association of TTP, OS, and circulating tumor tumor cell count.

OUTLINE: Patients receive carboplatin IV over 30-60 minutes on day 1, oral prednisone twice daily on days on days 1-21, and oral everolimus once daily on days 2-21 of course 1 and on days 1-21 of subsequent courses. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Blood and tumor tissue samples are collected periodically for pharmacodynamic, pharmacokinetic, and biomarker analysis.

After completion of study treatment, patients are followed up every 3 months.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 26 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Trial of Carboplatin and Everolimus (RAD001) in Metastatic Castrate Resistant Prostate Cancer (CRPC) Pretreated With Docetaxel Chemotherapy.
Study Start Date : February 2010
Actual Primary Completion Date : September 2013
Actual Study Completion Date : September 2013

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Carboplatin, RAD 001 & Prednisone

Carboplatin: AUC=4 by Calvert's formula (max dose 600 mg)*IV over 30-60 min, Day 1 of a 21 day cycle

RAD 001: 5 mg Orally daily, starting from Day 2 continuously

Prednisone 5 mg Orally twice daily, continuously

Drug: carboplatin
AUC = 5 by Calvert's formula, day 1 of each 21 day cycle
Other Name: Paraplatin®

Drug: RAD 001
5 mg orally starting on Day 2 then continuous
Other Names:
  • Afinitor®
  • Zortress
  • Everolimus

Drug: prednisone
5 mg orally twice a day starting on Day 1 then continuous
Other Names:
  • Deltasone
  • Liquid Pred
  • Meticorten
  • Orasone
  • Prednicen-M
  • Prednicot
  • Sterapred
  • Sterapred DS

Other: laboratory biomarker analysis
Samples will be collected from archival tissue.

Other: pharmacological study
Samples will be collected Cycle 1, day 1, 2 & 8 and Cycle 2, Day 1 & 2

Primary Outcome Measures :
  1. Time to Progression (TTP) [ Time Frame: Up to 63 days while on treatment, then up 90 days thereafter. From date of registration to date of progressive disease. ]
    Progression defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions taking as references the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions.

Secondary Outcome Measures :
  1. Number of Participants With Toxicity as Measured by NCI CTCAE v3.0 Criteria [ Time Frame: Day 1 of each cycle (every 21 days), through study completion, an average of 6 months ]
    Number of Participants with Grade 3/4 Toxicity as measured by NCI CTCAE v3.0 criteria

  2. PSA Response Rate [ Time Frame: Day 1 of each cycle (every 21 days), through study completion, an average of 6 months ]
    PSA response rate with response defined as => a 30% reduction in PSA

  3. Association of PSA Response Rate With Correlative Markers (Phospho mTOR, pAKT, and p70S6) [ Time Frame: Archival tissue will be collected if available. Optional biopsies pre-treatment and 24 hours after first everolimus and carboplatin dose ]
    PSA response defined as a decrease of 30% or more will be tabled against mTOR, pAKT, and p70S6 (1+, 2+, 3+ vs ND)

  4. Pharmacokinetics: Observed Carboplatin AUC Was Estimated Based on the Concentration in the 2.75-h Sample. [ Time Frame: Samples were collected Cycle 2, Day 1 ]
    Using a limited sampling model (i.e., AUC = 0.52 × C2.75h + 0.92) (Sorensen et al., 1993), observed carboplatin AUC was estimated based on the concentration in the 2.75-h sample.

  5. Overall Survival [ Time Frame: After treatment, participants will be contacted every 3 months up to 4 years ]
    Overall Survival as measured by the Kaplan-Meier method

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 120 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No


  • Histologically confirmed metastatic adenocarcinoma of the prostate
  • Objective disease progression or rising PSA despite androgen deprivation therapy and antiandrogen withdrawal (when applicable)
  • Progressed after ≥ 1 prior docetaxel-based chemotherapy regimen for metastatic disease

    • Patients with measurable disease* must have either rising PSA, increase in size of the lesion(s), or both

      • Patients with rising PSA as the only evidence of disease progression must demonstrate a rising trend with 2 successive elevations ≥ 1 week apart
    • Patients with no measurable disease must have a PSA ≥ 5 ng/mL or new areas of bony metastases on bone scan NOTE: *There is no minimum PSA requirement for patients with measurable disease
  • Documented to be castrate with a testosterone level of ≤ 0.5 ng/mL

    • Leuteinizing hormone-releasing hormone agonist therapy must be continued, if required to maintain castrate levels of testosterone
  • No uncontrolled brain or leptomeningeal metastases, including patients who continue to require glucocorticoids for brain or leptomeningeal metastases


  • Zubrod performance status 0-1
  • ANC ≥ 1,500/mm^3
  • Hemoglobin ≥ 9.0 g/dL
  • Platelet count ≥ 100,000/mm^3
  • Total bilirubin ≤ 1.5 times upper limit of normal (ULN)
  • Calculated creatinine clearance ≥ 50 mL/min OR serum creatinine ≤ 2 mg/dL
  • AST and/or ALT ≤ 2.5 times ULN if alkaline phosphatase normal OR alkaline phosphatase ≤ 4 times ULN if AST and/or ALT normal (for patients without documented bone metastases or for patients with liver metastases)
  • AST and/or ALT < 2.5 times ULN, without regard to alkaline phosphatase levels (for patients with documented bone metastases)
  • Fasting serum cholesterol ≤ 300 mg/dL OR ≤ 7.75 mmol/L AND fasting triglycerides ≤ 2.5 times ULN (in the case that one or both of these thresholds are exceeded, the patient is eligible only after initiation of appropriate lipid-lowering medication)
  • Fertile patients must use effective contraception during and for ≥ 6 months after completion of study treatment
  • Willing and able to comply with this study
  • Able to ingest oral medication
  • No other malignancies except non-melanoma skin cancer or any other adequately treated cancer in complete remission for ≥ 2 years
  • No significant traumatic injury within the past 4 weeks
  • No active (acute or chronic) or uncontrolled severe infections
  • No severe and/or uncontrolled medical conditions or other conditions that could affect study participation, including the following:

    • NYHA class III-IV symptomatic congestive heart failure
    • Unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction within the past 6 months, serious uncontrolled cardiac arrhythmia, or any other clinically significant cardiac disease
    • Severely impaired lung function as defined by spirometry and DLCO that is 50% of the normal predicted value and/or oxygen saturation that is ≤ 88% at rest on room air
    • Uncontrolled diabetes as defined by fasting serum glucose > 1.5 times ULN
    • Liver disease such as cirrhosis, chronic active hepatitis, or chronic persistent hepatitis
    • Known history of HIV seropositivity, hepatitis B or C
    • Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of everolimus (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection)
    • Active, bleeding diathesis
  • No known hypersensitivity to everolimus or other rapamycins (sirolimus, temsirolimus) or to their excipients
  • No history of noncompliance to medical regimens
  • No uncontrolled diabetes mellitus


  • See Disease Characteristics
  • At least 1 prior docetaxel based regimen for metastatic disease

    • Docetaxel based combination therapy or docetaxel alone considered as 1 regimen
  • No more than 2 prior chemotherapy regimens for metastatic disease
  • No prior treatment with an mTOR inhibitor (sirolimus, temsirolimus, everolimus)
  • At least 6 weeks since prior bicalutamide or nilutamide
  • At least 4 weeks since prior flutamide
  • More than 4 weeks since prior and no other concurrent investigational drugs
  • More than 4 weeks since prior and no other concurrent anticancer therapies (including chemotherapy, radiotherapy, or antibody-based therapy)
  • More than 4 weeks since prior and no concurrent major surgery (defined as requiring general anesthesia) and recovered
  • More than 1 week since prior and no concurrent immunization with attenuated live vaccines
  • No concurrent chronic, systemic treatment with corticosteroids or other immunosuppressive agents

    • Topical or inhaled corticosteroids are allowed
  • No concurrent prophylactic growth factors
  • Concurrent bisphosphonate therapy allowed

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01051570

Layout table for location information
United States, Illinois
Northshore University Health System
Evanston, Illinois, United States, 60201
United States, Michigan
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, United States, 48201-1379
Weisberg Cancer Treatment Center
Farmington Hills, Michigan, United States, 48334
United States, New Jersey
Cancer Institute of New Jersey
New Brunswick, New Jersey, United States, 08903
Sponsors and Collaborators
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)
Layout table for investigator information
Principal Investigator: Ulka N. Vaishampayan, M.D. Barbara Ann Karmanos Cancer Institute
Additional Information:
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Elisabeth Heath, Principal Investigator, Barbara Ann Karmanos Cancer Institute Identifier: NCT01051570    
Other Study ID Numbers: CDR0000663630
P30CA022453 ( U.S. NIH Grant/Contract )
First Posted: January 18, 2010    Key Record Dates
Results First Posted: August 25, 2014
Last Update Posted: December 1, 2020
Last Verified: November 2020
Keywords provided by Elisabeth Heath, Barbara Ann Karmanos Cancer Institute:
hormone-resistant prostate cancer
recurrent prostate cancer
stage IV prostate cancer
adenocarcinoma of the prostate
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Prostatic Diseases
Antineoplastic Agents
Anti-Inflammatory Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Antineoplastic Agents, Hormonal
Immunosuppressive Agents
Immunologic Factors